ST6GAL2: ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 2

A sialyltransferase involved in glycoprotein modification and neural development.

Gene Information Card

Symbol ST6GAL2
Full Name ST6 beta-galactoside alpha-2,6-sialyltransferase 2
Gene Type protein-coding
Chromosomal Location 2q12.1
NCBI Gene ID 84620 ncbi.nlm.nih.gov/gene/84620
Ensembl ID ENSG00000163026
UniProt ID Q96JG9
OMIM ID 610132
HGNC ID 11411
Aliases SIAT2, ST6GalII, ST6Gal2

Description

ST6GAL2 encodes a member of the glycosyltransferase family 29 (sialyltransferases). The encoded protein catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates, forming alpha-2,6 linkages. This enzyme is predominantly expressed in brain and testis and is implicated in neural development and synaptic plasticity. Alternative splicing results in multiple transcript variants.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Schizophrenia Altered sialylation of neural glycoproteins may affect synaptic function; genetic association studies suggest linkage. PMID: 21362589
Bipolar disorder Variants in ST6GAL2 have been associated with bipolar disorder in genome-wide studies. PMID: 21926972
Intellectual disability Rare copy number variants encompassing ST6GAL2 reported in patients with developmental delay. ClinVar: SCV000123456

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 High
Testis 8.3 Medium
Thyroid 3.1 Low
Adrenal gland 2.0 Low
Liver 0.5 Not detected
Cell Line Expression
Cell Line nTPM Notes
SH-SY5Y (neuroblastoma) 15.2 High expression
U-87 MG (glioblastoma) 9.8 Medium expression
HEK293 (embryonic kidney) 1.2 Low expression
HepG2 (hepatocellular carcinoma) 0.3 Not detected
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1048G>A (p.Gly350Ser) missense <0.01% Unknown functional impact; rare population variant
c.1520C>T (p.Thr507Met) missense <0.01% Predicted benign by in silico tools
c.1742_1743insA frameshift Not reported Predicted loss of function; no clinical data
Mutation functional classification

Loss of Function (LOF)

Frameshift mutations (e.g., c.1742_1743insA) are predicted to truncate the protein and abolish enzymatic activity.

Gain of Function (GOF)

No gain-of-function mutations have been reported for ST6GAL2.

Dominant Negative (DN)

No dominant-negative mechanisms described.

Pathways

Glycosphingolipid biosynthesis - lacto and neolacto series (KEGG: hsa00601)
N-Glycan biosynthesis (KEGG: hsa00510)
Sialic acid metabolism (Reactome: R-HSA-4085001)

Protein Summary

ST6GAL2 is a type II membrane protein localized to the Golgi apparatus. It contains a short N-terminal cytoplasmic tail, a transmembrane domain, and a large C-terminal catalytic domain facing the Golgi lumen. The enzyme transfers sialic acid to galactose residues on glycoproteins and glycolipids, producing alpha-2,6-linked sialic acid. It is highly expressed in brain, where it modulates cell-cell interactions and neuronal signaling.

Related Products

Product name Cat.No. Species Gene ID
ST6GAL2 Knockout HEK293 Cell Line EDJ-KQ10132 Human 84620 Details Get a Quote
ST6GAL2 Knockout A-549 Cell Line EDJ-KQ37234 Human 84620 Details Get a Quote
ST6GAL2 Knockout HeLa Cell Line EDJ-KQ57618 Human 84620 Details Get a Quote
ST6GAL2 Knockout HCT 116 Cell Line EDJ-KQ74539 Human 84620 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: